97 related articles for article (PubMed ID: 16465429)
1. Astatinated trastuzumab, a putative agent for radionuclide immunotherapy of ErbB2-expressing tumours.
Persson MI; Gedda L; Jensen HJ; Lundqvist H; Malmström PU; Tolmachev V
Oncol Rep; 2006 Mar; 15(3):673-80. PubMed ID: 16465429
[TBL] [Abstract][Full Text] [Related]
2. In vitro evaluation of the astatinated chimeric monoclonal antibody U36, a potential candidate for treatment of head and neck squamous cell carcinoma.
Nestor M; Persson M; van Dongen GA; Jensen HJ; Lundqvist H; Anniko M; Tolmachev V
Eur J Nucl Med Mol Imaging; 2005 Nov; 32(11):1296-304. PubMed ID: 16028065
[TBL] [Abstract][Full Text] [Related]
3. Direct procedure for the production of 211At-labeled antibodies with an epsilon-lysyl-3-(trimethylstannyl)benzamide immunoconjugate.
Lindegren S; Frost S; Bäck T; Haglund E; Elgqvist J; Jensen H
J Nucl Med; 2008 Sep; 49(9):1537-45. PubMed ID: 18703591
[TBL] [Abstract][Full Text] [Related]
4. Labeling of Anti-HER2 Nanobodies with Astatine-211: Optimization and the Effect of Different Coupling Reagents on Their in Vivo Behavior.
Dekempeneer Y; Bäck T; Aneheim E; Jensen H; Puttemans J; Xavier C; Keyaerts M; Palm S; Albertsson P; Lahoutte T; Caveliers V; Lindegren S; D'Huyvetter M
Mol Pharm; 2019 Aug; 16(8):3524-3533. PubMed ID: 31268724
[TBL] [Abstract][Full Text] [Related]
5. Evaluating the potential of 188Re-SOCTA-trastuzumab as a new radioimmunoagent for breast cancer treatment.
Luo TY; Tang IC; Wu YL; Hsu KL; Liu SW; Kung HC; Lai PS; Lin WJ
Nucl Med Biol; 2009 Jan; 36(1):81-8. PubMed ID: 19181272
[TBL] [Abstract][Full Text] [Related]
6. In vitro cytotoxicity of 211At-labeled trastuzumab in human breast cancer cell lines: effect of specific activity and HER2 receptor heterogeneity on survival fraction.
Akabani G; Carlin S; Welsh P; Zalutsky MR
Nucl Med Biol; 2006 Apr; 33(3):333-47. PubMed ID: 16631082
[TBL] [Abstract][Full Text] [Related]
7. In vivo examination of (188)Re(I)-tricarbonyl-labeled trastuzumab to target HER2-overexpressing breast cancer.
Chen KT; Lee TW; Lo JM
Nucl Med Biol; 2009 May; 36(4):355-61. PubMed ID: 19423002
[TBL] [Abstract][Full Text] [Related]
8. Comparative tissue distribution in mice of the alpha-emitter 211At and 131I as labels of a monoclonal antibody and F(ab')2 fragment.
Garg PK; Harrison CL; Zalutsky MR
Cancer Res; 1990 Jun; 50(12):3514-20. PubMed ID: 2340501
[TBL] [Abstract][Full Text] [Related]
9. In vivo activity of novel anti-ErbB2 antibody chA21 alone and with Paclitaxel or Trastuzumab in breast and ovarian cancer xenograft models.
Shen G; Huang H; Zhang A; Zhao T; Hu S; Cheng L; Liu J; Xiao W; Ling B; Wu Q; Song L; Wei W
Cancer Immunol Immunother; 2011 Mar; 60(3):339-48. PubMed ID: 21086124
[TBL] [Abstract][Full Text] [Related]
10. PC cell-derived growth factor stimulates proliferation and confers Trastuzumab resistance to Her-2-overexpressing breast cancer cells.
Kim WE; Serrero G
Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4192-9. PubMed ID: 16857791
[TBL] [Abstract][Full Text] [Related]
11. Effect of cetuximab in combination with alpha-radioimmunotherapy in cultured squamous cell carcinomas.
Nestor M; Sundström M; Anniko M; Tolmachev V
Nucl Med Biol; 2011 Jan; 38(1):103-12. PubMed ID: 21220133
[TBL] [Abstract][Full Text] [Related]
12. Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1.
Zsebik B; Citri A; Isola J; Yarden Y; Szöllosi J; Vereb G
Immunol Lett; 2006 Apr; 104(1-2):146-55. PubMed ID: 16384610
[TBL] [Abstract][Full Text] [Related]
13. Cetuximab enhances the anti-proliferative effect of trastuzumab in ERBB2 over-expressing breast cancer cells--preliminary study.
Uberall I; Krízová K; Steigerová J
Klin Onkol; 2011; 24(5):356-60. PubMed ID: 22070017
[TBL] [Abstract][Full Text] [Related]
14. Bispecific antibody to ErbB2 overcomes trastuzumab resistance through comprehensive blockade of ErbB2 heterodimerization.
Li B; Meng Y; Zheng L; Zhang X; Tong Q; Tan W; Hu S; Li H; Chen Y; Song J; Zhang G; Zhao L; Zhang D; Hou S; Qian W; Guo Y
Cancer Res; 2013 Nov; 73(21):6471-83. PubMed ID: 24046294
[TBL] [Abstract][Full Text] [Related]
15. Hyaluronan-induced masking of ErbB2 and CD44-enhanced trastuzumab internalisation in trastuzumab resistant breast cancer.
Pályi-Krekk Z; Barok M; Isola J; Tammi M; Szöllosi J; Nagy P
Eur J Cancer; 2007 Nov; 43(16):2423-33. PubMed ID: 17911008
[TBL] [Abstract][Full Text] [Related]
16. Treatment of HER2-positive breast carcinomatous meningitis with intrathecal administration of alpha-particle-emitting (211)At-labeled trastuzumab.
Boskovitz A; McLendon RE; Okamura T; Sampson JH; Bigner DD; Zalutsky MR
Nucl Med Biol; 2009 Aug; 36(6):659-69. PubMed ID: 19647172
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic efficacy of astatine-211-labeled trastuzumab on radioresistant SKOV-3 tumors in nude mice.
Palm S; Bäck T; Claesson I; Danielsson A; Elgqvist J; Frost S; Hultborn R; Jensen H; Lindegren S; Jacobsson L
Int J Radiat Oncol Biol Phys; 2007 Oct; 69(2):572-9. PubMed ID: 17869670
[TBL] [Abstract][Full Text] [Related]
18. Treatment of HER2-expressing breast cancer and ovarian cancer cells with alpha particle-emitting 227Th-trastuzumab.
Heyerdahl H; Krogh C; Borrebæk J; Larsen Å; Dahle J
Int J Radiat Oncol Biol Phys; 2011 Feb; 79(2):563-70. PubMed ID: 21195878
[TBL] [Abstract][Full Text] [Related]
19. Radioimmunotherapy with an
Takashima H; Koga Y; Manabe S; Ohnuki K; Tsumura R; Anzai T; Iwata N; Wang Y; Yokokita T; Komori Y; Mori D; Usuda S; Haba H; Fujii H; Matsumura Y; Yasunaga M
Cancer Sci; 2021 May; 112(5):1975-1986. PubMed ID: 33606344
[TBL] [Abstract][Full Text] [Related]
20. Reagents for astatination of biomolecules: comparison of the in vivo distribution and stability of some radioiodinated/astatinated benzamidyl and nido-carboranyl compounds.
Wilbur DS; Chyan MK; Hamlin DK; Kegley BB; Risler R; Pathare PM; Quinn J; Vessella RL; Foulon C; Zalutsky M; Wedge TJ; Hawthorne MF
Bioconjug Chem; 2004; 15(1):203-23. PubMed ID: 14733601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
